Overexpression of the Receptor for Advanced Glycation Endproducts (RAGE) Is Associated with Poor Prognosis in Gastric Cancer

Abstract

BackgroundThe receptor for advanced glycation endproducts (RAGE) is an oncogenic multidisciplinary trans-membranous receptor, which is overexpressed in multiple human cancers. Recently, it has been shown that RAGE is also involved in carcinogenesis and tumor invasion. In this study, we investigated the expression levels and prognostic value of RAGE in primary gastric cancers (GC).MethodsWe investigated RAGE expression in primary GC and paired normal gastric tissue by real-time quantitative RT-PCR (n = 30) and Western blotting analysis (n = 30). Additionally, we performed immunohistochemistry on 180 paraffin-embedded GC specimens, 69 matched normal specimens.ResultsRAGE was overexpressed in GC compared with the adjacent noncancerous tissues (P＜0.001), and higher RAGE expression significantly correlated with the histological grade (P = 0.002), nodal status(P = 0.025), metastasis status(P = 0.002), and American Joint Committee on Cancer stage (P = 0.020). Furthermore, upregulation of RAGE expression is an independent prognostic factor in multivariate analysis using the Cox regression model (P = 0.001).ConclusionsRAGE Overexpression may be a useful marker to predict GC progression and poor prognosis.

Receptor for advanced glycation end-products (RAGE) is overexpressed in human osteosarcoma and promotes the proliferation of osteosarcoma U-2OS cells in vitro

“…In gastric cancer, knockdown of RAGE reduced the proliferation and invasion of cells, implying that RAGE promotes the proliferation and invasion of cancer cells (Xu et al, 2013;Wang et al, 2015). In this study, we constructed OS U-2OS cells that overexpressed RAGE by transfecting a recombinant plasmid into the cells, and determined the function of RAGE in OS cells.…”

“…The interaction between RAGE and ligands plays an important role in various cellular processes, such as proliferation, apoptosis, autophagy, migration, and inflammation (Lin, 2006;Sims et al, 2010). RAGE is overexpressed in numerous types of cancers, such as gastric (Wang et al, 2015), oral (Su et al, 2015), pancreatic (Kang et al, 2014), colorectal (Dahlmann et al, 2014), and prostate (Zhao et al, 2014) cancers; inactivation of RAGE could inhibit the proliferation and invasion of cancer cells. Therefore, RAGE is a potential diagnostic biomarker and therapeutic target for OS.…”

Identification of genes associated with cancer progression and prognosis in lung adenocarcinoma: Analyses based on microarray from Oncomine and The Cancer Genome Atlas databases

“…AGER is one of a limited number of pathogen recognition receptors whose expression is downregulated in lung cancer (Rho, Roehrl, & Wang, 2009;Wang, Li, Yu, et al, 2015). However, AGER has been widely reported being highly expressed in various types of cancer, including ovarian cancer (Rahimi et al, 2017), breast cancer (Nankali et al, 2016), gastric cancer (Wang, Li, Ye, et al, 2015), and endometrial cancer (Zheng et al, 2016). In the current study, we found AGER was significantly and consistently downregulated at least 8.266-fold in LUAD according to four independent microarrays databases.…”

Increased Expression of the Receptor for Advanced Glycation End-Products (RAGE) Is Associated with Advanced Breast Cancer Stage

“…Wang et al [25] found that RAGE expression was up-regulated in human gastric cancer compared with normal tissues. They also showed that high levels of RAGE were associated with the histological grade and the metastasis status.…”